Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
Patients' responses to oncologists can help predict survival in chronic lymphocytic leukemia

Patients' responses to oncologists can help predict survival in chronic lymphocytic leukemia

Aircrews face highest risk of radiation-related cancer deaths

Aircrews face highest risk of radiation-related cancer deaths

Rare BTK mutation drives resistance to targeted therapies for blood cancer

Rare BTK mutation drives resistance to targeted therapies for blood cancer

Long telomeres linked to higher lymphoma risk in families

Long telomeres linked to higher lymphoma risk in families

Novel RNA molecule may influence patient survival in certain blood cancers

Novel RNA molecule may influence patient survival in certain blood cancers

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Researchers identify key differences between two subtypes of chronic lymphocytic leukemia

Researchers identify key differences between two subtypes of chronic lymphocytic leukemia

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

New GoT-Multi technology reveals how cancers evolve and resist treatment

New GoT-Multi technology reveals how cancers evolve and resist treatment

Nuclear missile workers are contracting cancer. They blame the bases.

Nuclear missile workers are contracting cancer. They blame the bases.

Study reveals early nicotinamide use reduces risk of aggressive skin cancers

Study reveals early nicotinamide use reduces risk of aggressive skin cancers

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

Research examines how cancer may invalidate forensic age-estimation tools

Research examines how cancer may invalidate forensic age-estimation tools

Cancer cells hide inside bone marrow fibroblasts to resist treatment

Cancer cells hide inside bone marrow fibroblasts to resist treatment

Immunoglobulin replacement therapy not associated with reduced risk of serious infections in patients with CLL

Immunoglobulin replacement therapy not associated with reduced risk of serious infections in patients with CLL

People with Chronic Lymphocytic Leukemia benefit from exercise yet lack personalized guidance

People with Chronic Lymphocytic Leukemia benefit from exercise yet lack personalized guidance

Maestro John Mauceri returns to the stage in renewed health

Maestro John Mauceri returns to the stage in renewed health

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

Next-generation "armored" CAR T cell therapy shows promising results in lymphoma patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.